The convalescent sera option for containing COVID-19.
作者信息
Casadevall Arturo, Pirofski Liise-Anne
机构信息
Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.
Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
出版信息
J Clin Invest. 2020 Apr 1;130(4):1545-1548. doi: 10.1172/JCI138003.
Abstract
摘要
相似文献
1
The convalescent sera option for containing COVID-19.使用康复期血清来控制新型冠状病毒肺炎。
J Clin Invest. 2020 Apr 1;130(4):1545-1548. doi: 10.1172/JCI138003.
2
Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.关于制备用于治疗COVID-19患者的免疫血浆的立场文件。
Transfus Apher Sci. 2020 Aug;59(4):102817. doi: 10.1016/j.transci.2020.102817. Epub 2020 May 21.
3
Active Therapy with Passive Immunotherapy May Be Effective in the Fight against COVID-19.主动疗法联合被动免疫疗法可能对对抗新冠病毒有效。
Clin Transl Sci. 2020 Sep;13(5):835-837. doi: 10.1111/cts.12816. Epub 2020 Jun 26.
4
Plasma from donors convalescent from SARS-CoV-2 infection-A matter of priorities.来自新冠病毒感染康复者的捐赠者血浆——优先事项问题
Transfus Clin Biol. 2020 Aug;27(3):167-168. doi: 10.1016/j.tracli.2020.05.002. Epub 2020 Jun 12.
5
Convalescent serum therapy for COVID-19: A 19th century remedy for a 21st century disease.新冠康复者血清疗法：一种治疗21世纪疾病的19世纪疗法。
PLoS Pathog. 2020 Aug 12;16(8):e1008735. doi: 10.1371/journal.ppat.1008735. eCollection 2020 Aug.
6
Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.关于制备用于治疗 COVID-19 患者的免疫血浆的立场文件。
Blood Transfus. 2020 May;18(3):163-166. doi: 10.2450/2020.0124-20.
7
Convalescent Plasma and COVID-19.康复期血浆与2019冠状病毒病
JAMA. 2020 Aug 4;324(5):524. doi: 10.1001/jama.2020.10699.
8
Convalescent serum lines up as first-choice treatment for coronavirus.康复血清成为治疗新冠病毒的首选疗法。
Nat Biotechnol. 2020 Jun;38(6):655-658. doi: 10.1038/d41587-020-00011-1.
9
Use of convalescent plasma in COVID-19 patients in China.中国新冠病毒肺炎康复者恢复期血浆在新冠肺炎患者中的应用。
Transfus Clin Biol. 2020 Aug;27(3):168-169. doi: 10.1016/j.tracli.2020.05.001. Epub 2020 May 16.
10
The resurgence of convalescent plasma therapy.恢复期血浆疗法的复兴。
Lancet Haematol. 2020 May;7(5):e353. doi: 10.1016/S2352-3026(20)30117-4.
引用本文的文献
1
COVID-19 Vaccination in Patients with Hematological Malignances.血液系统恶性肿瘤患者的新冠病毒疫苗接种
Vaccines (Basel). 2025 Apr 25;13(5):465. doi: 10.3390/vaccines13050465.
2
Therapeutic Approaches for COVID-19: A Review of Antiviral Treatments, Immunotherapies, and Emerging Interventions.2019冠状病毒病的治疗方法：抗病毒治疗、免疫疗法及新兴干预措施综述
Adv Ther. 2025 May 8. doi: 10.1007/s12325-025-03218-3.
3
mGem: A quarter century with the Pirofski-Casadevall damage response framework-a dynamic construct for understanding microbial pathogenesis.mGem：与皮罗夫斯基-卡萨德瓦尔损伤反应框架相伴的二十五年——一个理解微生物致病机制的动态结构
mBio. 2025 Mar 12;16(3):e0294524. doi: 10.1128/mbio.02945-24. Epub 2025 Feb 11.
4
Coagulation Profile of Convalescent Plasma Donors and Recipients.康复期血浆捐献者和接受者的凝血指标
Clin Appl Thromb Hemost. 2025 Jan-Dec;31:10760296251317522. doi: 10.1177/10760296251317522.
5
SARS-CoV-2 IgG antibodies in COVID-19 convalescent plasma and conventional plasma units.新冠康复者血浆和常规血浆单位中的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）IgG抗体
Transfusion. 2025 Mar;65(3):446-452. doi: 10.1111/trf.18139. Epub 2025 Jan 22.
6
Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients.COVID-19 恢复期血浆滴度变化及受者 SARS-CoV2 特异性体液免疫对住院患者生存的影响。
PLoS One. 2024 Oct 24;19(10):e0309449. doi: 10.1371/journal.pone.0309449. eCollection 2024.
7
A program for real-time surveillance of SARS-CoV-2 genetics.实时监测 SARS-CoV-2 遗传学的程序。
Sci Rep. 2024 Aug 30;14(1):20249. doi: 10.1038/s41598-024-70697-9.
8
Monoclonal IgY antibodies: advancements and limitations for immunodiagnosis and immunotherapy applications.单克隆IgY抗体：免疫诊断和免疫治疗应用的进展与局限
Ther Adv Vaccines Immunother. 2024 Jul 25;12:25151355241264520. doi: 10.1177/25151355241264520. eCollection 2024.
9
Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update.COVID-19治疗潜在药物和疫苗的临床前与临床研究：近期更新的综合综述
Clin Pathol. 2024 Jul 26;17:2632010X241263054. doi: 10.1177/2632010X241263054. eCollection 2024 Jan-Dec.
10
Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients with COVID-19: The Co-CLARITY Trial.康复期血浆作为COVID-19住院患者的辅助治疗：Co-CLARITY试验。
Acta Med Philipp. 2024 Feb 15;58(2):5-15. doi: 10.47895/amp.vi0.4903. eCollection 2024.
本文引用的文献
1
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry.抗体依赖增强作用促进冠状病毒进入的分子机制。
J Virol. 2020 Feb 14;94(5). doi: 10.1128/JVI.02015-19.
2
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.埃博拉病毒病治疗的随机、对照试验。
N Engl J Med. 2019 Dec 12;381(24):2293-2303. doi: 10.1056/NEJMoa1910993. Epub 2019 Nov 27.
3
The Roles of Host and Viral Antibody Fc Receptors in Herpes Simplex Virus (HSV) and Human Cytomegalovirus (HCMV) Infections and Immunity.宿主和病毒抗体 Fc 受体在单纯疱疹病毒 (HSV) 和人类巨细胞病毒 (HCMV) 感染和免疫中的作用。
Front Immunol. 2019 Sep 6;10:2110. doi: 10.3389/fimmu.2019.02110. eCollection 2019.
4
Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease.Fc 介导的呼吸道合胞病毒感染和疾病中的抗体效应功能。
Front Immunol. 2019 Mar 22;10:548. doi: 10.3389/fimmu.2019.00548. eCollection 2019.
5
A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus.Fc 功能在治疗性单克隆抗体预防埃博拉病毒中的作用。
Cell Host Microbe. 2018 Aug 8;24(2):221-233.e5. doi: 10.1016/j.chom.2018.07.009.
6
Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience.中东呼吸综合征冠状病毒感染中恢复期血浆输注治疗的挑战：单中心经验
Antivir Ther. 2018;23(7):617-622. doi: 10.3851/IMP3243. Epub 2018 Jun 20.
7
Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study.新型转染色体牛源多克隆人抗中东呼吸综合征冠状病毒抗体的安全性和耐受性：一项 1 期随机、双盲、单次递增剂量研究。
Lancet Infect Dis. 2018 Apr;18(4):410-418. doi: 10.1016/S1473-3099(18)30002-1. Epub 2018 Jan 9.
8
Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone.在塞拉利昂弗里敦对恢复期全血治疗埃博拉病毒病的评估。
J Infect. 2017 Mar;74(3):302-309. doi: 10.1016/j.jinf.2016.11.009. Epub 2016 Nov 17.
9
Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia.沙特阿拉伯：使用恢复期血浆免疫疗法治疗中东呼吸综合征冠状病毒感染的可行性
Emerg Infect Dis. 2016 Sep;22(9):1554-61. doi: 10.3201/eid2209.151164.
10
Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma.使用康复期血浆成功治疗人感染H7N9禽流感。
Int J Infect Dis. 2015 Dec;41:3-5. doi: 10.1016/j.ijid.2015.10.009. Epub 2015 Oct 23.
Zotero 插件